{"id":2384,"date":"2017-11-03T13:24:36","date_gmt":"2017-11-03T07:54:36","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=2384"},"modified":"2021-07-24T12:56:51","modified_gmt":"2021-07-24T07:26:51","slug":"notizia-55","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/notizia-55","title":{"rendered":"AstraZeneca and Incyte Collaborate; Tocagen\u2019s therapy; FDA warns companies;FDA Revokes"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a001186dc8da\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a001186dc8da\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-55\/#AstraZeneca_and_Incyte_are_about_to_enter_into_Clinical_Trial_Collaboration_in_Early_Lung_Cancer\" >AstraZeneca and Incyte are about to enter into Clinical Trial Collaboration in Early Lung Cancer<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-55\/#Tocagens_combo_therapy_enters_directly_into_phase_3_trials_after_getting_approval_from_FDA\" >Tocagen\u2019s combo therapy enters directly into phase 3 trials after getting approval from FDA<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-55\/#FDA_warns_companies_marketing_unverified_products_derived_from_marijuana_claiming_cancer_treatment_or_cure\" >FDA warns companies marketing unverified products, derived from marijuana, claiming cancer treatment or cure<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-55\/#FDA_about_to_Revoke_Claims_regarding_Heart_Health_benefits_of_Soy\" >FDA about to Revoke Claims regarding Heart Health benefits of Soy<\/a><\/li><\/ul><\/nav><\/div>\n<h4><span class=\"ez-toc-section\" id=\"AstraZeneca_and_Incyte_are_about_to_enter_into_Clinical_Trial_Collaboration_in_Early_Lung_Cancer\"><\/span><span style=\"color: #000000;\"><strong>AstraZeneca and Incyte are about to enter into Clinical Trial Collaboration in Early Lung Cancer<\/strong><\/span><span class=\"ez-toc-section-end\"><\/span><\/h4>\n<ul>\n<li><span style=\"color: #000000;\">The exclusive collaboration for the study population allows the two companies to conduct a <strong>Phase 3<\/strong>\u00a0trial. Aim of this study is to evaluate patients with locally-advanced (<strong>Stage III<\/strong>), unresectable non-small cell lung cancer (<strong>NSCLC<\/strong>), whose disease has not progressed following platinum-based chemotherapy concurrent with radiation therapy (<strong>CRT<\/strong>).<\/span><\/li>\n<\/ul>\n<h4><span class=\"ez-toc-section\" id=\"Tocagens_combo_therapy_enters_directly_into_phase_3_trials_after_getting_approval_from_FDA\"><\/span><span style=\"color: #000000;\"><strong>Tocagen\u2019s combo therapy enters directly into phase 3 trials after getting approval from FDA<\/strong><\/span><span class=\"ez-toc-section-end\"><\/span><\/h4>\n<ul>\n<li><span style=\"color: #000000;\"><strong>Tocagen<\/strong> is moving directly into a <strong>phase 3<\/strong> trial with its combo therapy <strong>Toca 511<\/strong> and <strong>Toca FC<\/strong> gene therapy in cancer and thus needs more patients. To facilitate the process FDA has provided a <strong>$2 million orphan drug grant<\/strong> payable over four years.<\/span><\/li>\n<\/ul>\n<h4><span class=\"ez-toc-section\" id=\"FDA_warns_companies_marketing_unverified_products_derived_from_marijuana_claiming_cancer_treatment_or_cure\"><\/span><span style=\"color: #000000;\"><strong>FDA warns companies marketing unverified products, derived from marijuana, claiming cancer treatment or cure<\/strong><\/span><span class=\"ez-toc-section-end\"><\/span><\/h4>\n<ul>\n<li><span style=\"color: #000000;\">Under the U.S. Food and Drug Administration\u2019s ongoing efforts to protect consumers from health fraud. The agency has recently issued warning letters to four companies. Action is taken against the companies illegally selling <strong>marijuana products<\/strong> online claiming to prevent, diagnose, treat, or cure cancer without any evidence to support the same.<\/span><\/li>\n<\/ul>\n<h4><span class=\"ez-toc-section\" id=\"FDA_about_to_Revoke_Claims_regarding_Heart_Health_benefits_of_Soy\"><\/span><span style=\"color: #000000;\">FDA about to Revoke Claims regarding Heart Health benefits of Soy<\/span><span class=\"ez-toc-section-end\"><\/span><\/h4>\n<ul>\n<li><span style=\"color: #000000;\">In a recent statement <strong>Susan Mayne<\/strong>, director of the Center for Food Safety and Applied Nutrition at the FDA has said that, the relationship between <strong>soy protein<\/strong> and <strong>heart health<\/strong> does not meet the rigorous standard for an FDA-authorized health claim.<\/span><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>AstraZeneca and Incyte are about to enter into Clinical Trial Collaboration in Early Lung Cancer The exclusive collaboration for the study population allows the two companies to conduct a Phase 3\u00a0trial. Aim of this study is to evaluate patients with locally-advanced (Stage III), unresectable non-small cell lung cancer (NSCLC), whose disease has not progressed following [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2303,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[96,1118,137,927,1112,204,1108,704,258,1122,1107,1117,381,1111,1116,639,1119,1109,1121,1120,1114,1115,1113,1110],"industry":[17225],"therapeutic_areas":[17242,17228],"class_list":["post-2384","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-astrazeneca","tag-business-research","tag-cancer","tag-cancer-treatment","tag-crt","tag-delveinsight","tag-early-lung-cancer","tag-fda","tag-gene-therapy","tag-heart-health","tag-incyte","tag-marijuana","tag-market-research","tag-nsclc","tag-orphan-drug-grant","tag-pharma-news","tag-pharmaceutical","tag-phase-3","tag-soy-protein","tag-susan-mayne","tag-toca-511","tag-toca-fc","tag-tocagen","tag-unresectable-non-small-cell-lung-cancer","industry-pharmaceutical","therapeutic_areas-cardiovascular-diseases","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>AstraZeneca and Incyte Collaboration; Tocagen\u2019s therapy<\/title>\n<meta name=\"description\" content=\"The exclusive collaboration for the study population allows the two companies to conduct a Phase 3\u00a0trial. Aim of this study...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-55\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AstraZeneca and Incyte Collaboration; Tocagen\u2019s therapy\" \/>\n<meta property=\"og:description\" content=\"The exclusive collaboration for the study population allows the two companies to conduct a Phase 3\u00a0trial. Aim of this study...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/notizia-55\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2017-11-03T07:54:36+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:26:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/09\/09021345\/news-750x315.gif\" \/>\n\t<meta property=\"og:image:width\" content=\"750\" \/>\n\t<meta property=\"og:image:height\" content=\"315\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/gif\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AstraZeneca and Incyte Collaboration; Tocagen\u2019s therapy","description":"The exclusive collaboration for the study population allows the two companies to conduct a Phase 3\u00a0trial. Aim of this study...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/notizia-55","og_locale":"en_US","og_type":"article","og_title":"AstraZeneca and Incyte Collaboration; Tocagen\u2019s therapy","og_description":"The exclusive collaboration for the study population allows the two companies to conduct a Phase 3\u00a0trial. Aim of this study...","og_url":"https:\/\/www.delveinsight.com\/blog\/notizia-55","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2017-11-03T07:54:36+00:00","article_modified_time":"2021-07-24T07:26:51+00:00","og_image":[{"width":750,"height":315,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/09\/09021345\/news-750x315.gif","type":"image\/gif"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-55","url":"https:\/\/www.delveinsight.com\/blog\/notizia-55","name":"AstraZeneca and Incyte Collaboration; Tocagen\u2019s therapy","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-55#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-55#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/09\/09021345\/news-750x315.gif","datePublished":"2017-11-03T07:54:36+00:00","dateModified":"2021-07-24T07:26:51+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"The exclusive collaboration for the study population allows the two companies to conduct a Phase 3\u00a0trial. Aim of this study...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/notizia-55"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-55#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/09\/09021345\/news-750x315.gif","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/09\/09021345\/news-750x315.gif","width":750,"height":315,"caption":"Notizia"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/09\/09021345\/news-750x315-300x126.gif","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">AstraZeneca<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">business research<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Cancer Treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">CRT<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Early Lung Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">FDA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Gene therapy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">heart health<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Incyte<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">marijuana<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Market Research<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">NSCLC<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">orphan drug grant<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharmaceutical<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Phase 3<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">soy protein<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Susan Mayne<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Toca 511<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Toca FC<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Tocagen<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">unresectable non-small cell lung cancer<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">AstraZeneca<\/span>","<span class=\"advgb-post-tax-term\">business research<\/span>","<span class=\"advgb-post-tax-term\">Cancer<\/span>","<span class=\"advgb-post-tax-term\">Cancer Treatment<\/span>","<span class=\"advgb-post-tax-term\">CRT<\/span>","<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">Early Lung Cancer<\/span>","<span class=\"advgb-post-tax-term\">FDA<\/span>","<span class=\"advgb-post-tax-term\">Gene therapy<\/span>","<span class=\"advgb-post-tax-term\">heart health<\/span>","<span class=\"advgb-post-tax-term\">Incyte<\/span>","<span class=\"advgb-post-tax-term\">marijuana<\/span>","<span class=\"advgb-post-tax-term\">Market Research<\/span>","<span class=\"advgb-post-tax-term\">NSCLC<\/span>","<span class=\"advgb-post-tax-term\">orphan drug grant<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">pharmaceutical<\/span>","<span class=\"advgb-post-tax-term\">Phase 3<\/span>","<span class=\"advgb-post-tax-term\">soy protein<\/span>","<span class=\"advgb-post-tax-term\">Susan Mayne<\/span>","<span class=\"advgb-post-tax-term\">Toca 511<\/span>","<span class=\"advgb-post-tax-term\">Toca FC<\/span>","<span class=\"advgb-post-tax-term\">Tocagen<\/span>","<span class=\"advgb-post-tax-term\">unresectable non-small cell lung cancer<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 9 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Nov 3, 2017","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Nov 3, 2017 1:24 pm","modified":"Updated on Jul 24, 2021 12:56 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2384","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=2384"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2384\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/2303"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=2384"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=2384"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=2384"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=2384"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=2384"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}